Monday, July 16, 2012

Charles Crispin: Healthcare risk analysis expert

A brilliant businessman, Charles Crispin served as senior vice president of Evergreen Re, the largest health plan reinsurance broker in the United States. From 1997 until 2010, Crispin helped the company take the lead in the health risks analysis market.


Charles Crispin Image Credit: Eventbrite.com


Under Crispin’s able leadership, Evergreen was able to create strategic direction and it had grown exponentially in the following years since he came aboard. The firm’s rapid growth eventually helped Evergreen boast of the best available proprietary analysis processes that enable the clients to understand and predict insurance risks. On the development of these processes and top-of-the line services, Crispin served a significant role.


Prior to his association with Evergreen Re, Charles Crispin formed his owned healthcare consulting firm, sat on several company boards, served one of the nation’s fastest growing Medicare Risk plans, and even co-founded the actuarial consulting firm Reden & Anders (Ingenix) and made it one of his formation grounds. A managed care operations and healthcare economics expert, Crispin was involved in many important partnerships with respected companies, individuals, and organizations with business operations on areas related to health plans and integrated delivery systems.


Charles Crispin Image Credit: Flickr.com/wtkn


In 2004, Crispin expanded Evergreen’s services by developing Evergreen Rx, the firm’s pharmacy consulting practice. It was a successful initiative that boosted the company’s reputation as one of the leading experts in pharmaceutical issues and biologics.


In 2007, Crispin sold Evergreen Re to Brown & Brown (NYSE:BRO) but continued in his role as president and CEO until May 2010. Today, he still caters to a high-quality client base while enjoying his time at his Hammock Walk Ranch.


Charles Crispin Image Credit: Healthwebsummit.com


For more information on Charles Crispin, visit this Facebook page.

No comments:

Post a Comment